Not only is Sanofi Pasteur at the forefront of conquering newly targeted diseases, but the company is also leading the way in expanding immunization across all age groups, including adolescents and the elderly. This leadership has translated into outstanding success in the industry.
Sanofi Pasteur is interested in partners who will share in the pursuit of innovation and the company’s drive for excellence while becoming a part of its market success story. “We welcome the opportunity to evaluate technologies related to the development and production of human vaccines, both prophy-lactic and therapeutic, including vaccines for chronic infectious diseases,” said Roman Chicz, global head of external research and development.
Sanofi Pasteur is improving global human health by the discovery, development, manufacture and supply of vaccines for the prevention and treatment of infectious diseases.
Patient receiving their annual flu shot.
Sanofi Pasteur has a strong commitment to the establishment of research and development partnerships with major universities, research institutes, government agencies, biotechnology companies, non-government organizations and contract research organizations. The company’s collaborations cover virtually all aspects of vaccine development, including early-stage research.
Examples of current partnerships and technology investments include a protective monoclonal antibody against respiratory syncytial virus (RSV) infection in infants; vaccine candidates against RSV, herpes simplex virus, Streptococcus pneumoniae and broadly protective influenza; pediatric combination vaccines; large-scale cell culture-based virus production; adjuvants and immunomodulators; conjugate vaccine production; and vaccine delivery systems. In addition, the company partnered in 2018 with Translate Bio on their mRNA platform.
A company that partners with Sanofi Pasteur interacts with a multidisciplinary team with years of experience in working to ensure that partnerships are executed successfully and are nurtured for the mutual benefit of all parties.
This approach utilizes the value-added Sanofi Pasteur alliance management capability, which focuses on the relationship by the facilitation of open communication, trust, understanding and clear expectations across the project lifespan.
Combined with the technical competency of the alliance, this balance provides a well-rounded environment in which novel technologies can flourish. Currently, 100% of our preclinical portfolio and ~50% of our clinical portfolio has a partnering component.
Sanofi Pasteur welcomes information about new partnership opportunities. Each opportunity is carefully evaluated and reviewed by our dedicated team.